Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Crinetics...
Cleerly Raises $106 Million in Funding Led by Insight Partners to Revolutionize Heart Disease Care December 4, 2024 (DENVER) – Today Cleerly, a leader in advanced cardiovascular imaging, announced the successful closure of its Series C extension funding round, raising...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two...
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients Agency feedback from Type C meeting process supports the company’s proposed clinical development plans to expand the upliFT-D trial to...
Recent Comments